Ionis To Get Head Start On Arrowhead With Tryngolza Launch
The antisense oligonucleotide specialist is ready to launch its rare disease therapy Tryngolza but could face competition from a more potent rival by mid-2025.
The antisense oligonucleotide specialist is ready to launch its rare disease therapy Tryngolza but could face competition from a more potent rival by mid-2025.